Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging

Blood Cancer Journal

Volumn 5, Issue , 2015, Pages

  Kastritis, E ^a   Gavriatopoulou, M ^a   Dimopoulos, M A ^a   Eleutherakis Papaiakovou, E ^a   Kanellias, N ^a   Roussou, M ^a   Pamboucas, C ^a   Toumanidis, S T ^a   Terpos, E ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMINO TERMINAL TELOPEPTIDE; BETA 2 MICROGLOBULIN; CARBOXY TERMINAL TELOPEPTIDE; DEXAMETHASONE; IMMUNOGLOBULIN G; LENALIDOMIDE; MELPHALAN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SOLUBLE RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; BONE ATROPHY; BONE MARROW CELL; BONE METABOLISM; BONE REMODELING; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GAMMOPATHY; HEART INJURY; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOMA; OSSIFICATION; OSTEOCLAST ACTIVITY; OSTEOLYSIS; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PROGNOSIS; PROSPECTIVE STUDY; STAGING; SURVIVAL TIME;

EID: 84930638999     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.43     Document Type: Article

References (31)

1. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013; 121: 5124-5130.
2. Michael M, Kastritis E, Delimpassi S, Michalis E, Repoussis P, Kyrtsonis MC et al. Clinical characteristics and outcome of primary systemic light-chain amyloidosis in Greece. Clin Lymphoma Myeloma Leuk 2010; 10: 56-61.
3. Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007; 21: 1875-1884.
4. Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2004; 126: 686-689.
5. Terpos E, Anagnostopoulos A, Kastritis E, Bamias A, Tsionos K, Dimopoulos MA. Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1a) in Waldenström macroglobulinaemia. Br J Haematol 2006; 133: 301-304.
6. M'bappé P, Grateau G. Osteo-articular manifestations of amyloidosis. Best Pract Res Clin Rheumatol 2012; 26: 459-475.
7. Prokaeva T, Spencer B, Kaut M, Ozonoff A, Doros G, Connors LH et al. Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival. Arthritis Rheum 2007; 56: 3858-3868.
8. Kramer MR, van Dijk JM, Hadas I, Hershko C. Destructive bone lesions in primary amyloidosis. Postgrad Med J 1986; 62: 1037-1041.
9. Pambuccian SE, Horyd ID, Cawte T, Huvos AG. Amyloidoma of bone, a plasma cell/ plasmacytoid neoplasm. Report of three cases and review of the literature. Am J Surg Pathol 1997; 21: 179-186.
10. Schonland SO, Hansmann J, Mechtersheimer G, Goldschmidt H, Ho AD, Hegenbart U. Bone involvement in patients with systemic AL amyloidosis mimics lytic myeloma bone disease. Haematologica 2008; 93: 955-956.
11. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328.
12. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30: 4541-4549.
13. Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R et al. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia 2010; 24: 1700-1712.
14. Terpos E, de la Fuente J, Szydlo R, Hatjiharissi E, Viniou N, Meletis J et al. Tartrateresistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer 2003; 106: 455-457.
15. Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005; 16: 1223-1231.
16. Terpos E, Berenson J, Cook RJ, Lipton A, Coleman RE. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 2010; 24: 1043-1049.
17. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wntsignaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483-2494.
18. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003; 102: 1064-1069.
19. Seidel C, Hjertner Ø, Abildgaard N, Heickendorff L, Hjorth M, Westin J et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001; 98: 2269-2271.
20. Terpos E, Christoulas D, Kastritis E, Papatheodorou A, Kanellias N, Migkou M et al. High C-terminal cross-linking telopeptide of collagen type-I (CTX) predicts for poor overall survival in patients with multiple myeloma who receive frontline therapy with immunomodulatory drugs (IMiDs) but not with bortezomib-based regimens. Blood (ASH Annu Meeting Abstr) 2012; 120: 935.
21. Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003; 123: 106-109.
22. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751-3757.
23. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121: 3420-3427.
24. Røysland R, Masson S, Omland T, Milani V, Bjerre M, Flyvbjerg A et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI-HF trial. Am Heart J 2010; 160: 286-293.
25. Aramburu-Bodas O, García-Casado B, Salamanca-Bautista P, Guisado-Espartero ME, Arias-Jiménez JL et al. Relationship between osteoprotegerin and mortality in decompensated heart failure with preserved ejection fraction. J Cardiovasc Med 16: 438-443.
26. Ueland T, Dahl CP, Kjekshus J, Hulthe J, Böhm M, Mach F et al. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail 2011; 4: 145-152.
27. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008; 51: 627-633.
28. Pedersen S, Mogelvang R, Bjerre M, Frystyk J, Flyvbjerg A, Galatius S et al. Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Cardiology 2012; 123: 31-38.
29. Fuernau G, Zaehringer S, Eitel I, de Waha S, Droppa M, Desch S et al. Osteoprotegerin in ST-elevation myocardial infarction: prognostic impact and association with markers of myocardial damage by magnetic resonance imaging. Int J Cardiol 2013; 167: 2134-2139.
30. Jensen JK, Ueland T, Atar D, Gullestad L, Mickley H, Aukrust P, Januzzi JL. Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. J Intern Med 2010; 267: 410-417.
31. Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005; 111: 2461-2468.